AN ACT TO ESTABLISH A SCREENING AND APPROVAL PROGRAM FOR THE OVER-THE-COUNTER AVAILABILITY AND RETAIL SALE OF PRODUCTS THAT CONTAIN ANY SUBSTANCE WITH THE POTENTIAL TO BE RECREATIONALLY USED OR ABUSED; TO DEFINE CERTAIN TERMS; TO REQUIRE THE STATE DEPARTMENT OF HEALTH TO ADMINISTER THE PROGRAM; TO REQUIRE THE STATE HEALTH OFFICER TO APPROVE OR DENY THE OVER-THE-COUNTER AVAILABILITY AND RETAIL SALE OF PRODUCTS THAT CONTAIN ANY SUBSTANCE WITH THE POTENTIAL TO BE RECREATIONALLY USED OR ABUSED; TO ESTABLISH AN APPEALS PROCESS AVAILABLE TO THE MANUFACTURER OR DISTRIBUTOR OF A PRODUCT THAT WAS DENIED BY THE STATE HEALTH OFFICER; TO REQUIRE THE DEPARTMENT TO ESTABLISH RULES AND REGULATIONS NECESSARY TO IMPLEMENT AND ADMINISTER THE PROGRAM; TO PROVIDE AN EXCEPTION FOR ORDINANCES AND REGULATIONS OF MUNICIPALITIES AND COUNTIES ENACTED BEFORE JULY 1, 2025, WHICH LIMIT OR PROHIBIT SUCH PRODUCTS; AND FOR RELATED PURPOSES.
Summary
HB 1639 creates a new screening and approval program within the Mississippi State Department of Health for over-the-counter products that contain substances that could be recreationally used or abused. The bill defines that category broadly to include substances used without physician supervision, substances used for enjoyment or perceived health benefits, and substances that are unpredictable, potentially harmful, or associated with dependence and other social or health problems. The bill specifically references products containing substances such as bath salts, kratom, and tianeptine as examples of the kinds of products the program is intended to address.
Under the bill, the State Health Officer, or a designee, would have authority to approve or deny the retail sale and over-the-counter availability of such products based on anecdotal, scientific, or other relevant evidence. Manufacturers or distributors whose products are denied would have a right to appeal to the State Board of Health within 30 days, and the department would be required to adopt rules and regulations to administer the program. The act would take effect July 1, 2026.
Impact
HB 1639 would add a new layer of state oversight over the retail sale of certain consumer products containing potentially abusable substances, shifting approval authority to the State Department of Health and the State Health Officer. It would affect manufacturers, distributors, and retailers of products such as kratom, tianeptine, bath salts, and similar substances by requiring state approval before over-the-counter sale can continue or begin. The bill also preserves local authority by stating that municipal and county ordinances or regulations limiting or prohibiting these products are not preempted, including measures enacted before and after the bill’s effective date.
Sentiment
Based on the bill text and available context, the measure appears to be framed as a public health and consumer safety bill aimed at reducing access to products viewed as risky or prone to misuse. The overall tone is regulatory and precautionary, with the legislature delegating broad discretion to health officials to evaluate products using multiple forms of evidence. No committee transcript or recorded vote information is available, so there is no documented public debate or formal vote sentiment in the provided materials.
Contention
The main point of potential contention is the breadth of the bill’s definition of substances that may be subject to approval or denial, which gives the State Board of Health and State Health Officer substantial discretion. Manufacturers and distributors may object to the possibility of denial based on anecdotal as well as scientific evidence, and to the uncertainty this creates for products that are legally sold over the counter. Another likely issue is the bill’s interaction with local regulation: while it preserves municipal and county restrictions, that feature could be viewed either as an important local control safeguard or as a patchwork approach that complicates statewide retail compliance.